FGF19 and neoplasm: Treatment with 8 mg Lenvatinib did not lead to an increase in serum FGF19 levels (ratio 1.23) or a decrease in Ang-2 (ratio 1.24) levels at 4 weeks, and repeat CT scans showed marked tumor progression in the liver (progressive disease; PD) at 7 weeks (e).